Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

In acute promyelocytic leukemia (APL) low BAALC gene expression identifies a patient group with favorable overall survival and improved relapse free survival.

Nolte F, Hecht A, Reinwald M, Nowak D, Nowak V, Hanfstein B, Faldum A, Büchner T, Spiekermann K, Sauerland C, Hofmann WK, Lengfelder E.

Leuk Res. 2013 Apr;37(4):378-82. doi: 10.1016/j.leukres.2012.11.018. Epub 2012 Dec 31.

PMID:
23287429
2.

BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.

Baldus CD, Tanner SM, Ruppert AS, Whitman SP, Archer KJ, Marcucci G, Caligiuri MA, Carroll AJ, Vardiman JW, Powell BL, Allen SL, Moore JO, Larson RA, Kolitz JE, de la Chapelle A, Bloomfield CD.

Blood. 2003 Sep 1;102(5):1613-8. Epub 2003 May 15.

3.

BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications.

Baldus CD, Thiede C, Soucek S, Bloomfield CD, Thiel E, Ehninger G.

J Clin Oncol. 2006 Feb 10;24(5):790-7. Epub 2006 Jan 17.

PMID:
16418499
4.

Risk assessment in patients with acute myeloid leukemia and a normal karyotype.

Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T.

Clin Cancer Res. 2005 Feb 15;11(4):1416-24. Erratum in: Clin Cancer Res. 2005 Aug 1;11(15):5659.

5.

BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients.

Damiani D, Tiribelli M, Franzoni A, Michelutti A, Fabbro D, Cavallin M, Toffoletti E, Simeone E, Fanin R, Damante G.

Am J Hematol. 2013 Oct;88(10):848-52. doi: 10.1002/ajh.23516. Epub 2013 Jul 23.

6.

Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome.

Baldus CD, Martus P, Burmeister T, Schwartz S, Gökbuget N, Bloomfield CD, Hoelzer D, Thiel E, Hofmann WK.

J Clin Oncol. 2007 Aug 20;25(24):3739-45. Epub 2007 Jul 23.

PMID:
17646667
7.

Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129.

Gallagher RE, Yeap BY, Bi W, Livak KJ, Beaubier N, Rao S, Bloomfield CD, Appelbaum FR, Tallman MS, Slack JL, Willman CL.

Blood. 2003 Apr 1;101(7):2521-8. Epub 2002 Dec 5.

8.

The PML-RAR alpha transcript in long-term follow-up of acute promyelocytic leukemia patients.

Gameiro P, Vieira S, Carrara P, Silva AL, Diamond J, Botelho de Sousa A, Mehta AB, Prentice HG, Guimarães JE, Hoffbrand AV, Foroni L, Parreira A.

Haematologica. 2001 Jun;86(6):577-85.

9.

Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia.

Santamaría C, Chillón MC, Fernández C, Martín-Jiménez P, Balanzategui A, García Sanz R, San Miguel JF, González MG.

Haematologica. 2007 Mar;92(3):315-22.

10.

Low MDR1 and BAALC expression identifies a new subgroup of intermediate cytogenetic risk acute myeloid leukemia with a favorable outcome.

Guo X, Shi P, Chen F, Zha J, Liu B, Li R, Dong H, Zheng H, Xu B.

Blood Cells Mol Dis. 2014 Sep;53(3):144-8. doi: 10.1016/j.bcmd.2014.05.001. Epub 2014 May 20.

PMID:
24855032
13.

Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial.

Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F, Saglio G, Martinelli G, Petti MC, Santoro A, Pelicci PG, Mandelli F, Biondi A, Lo Coco F.

Blood. 1998 Aug 1;92(3):784-9.

14.

AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study.

Avvisati G, Lo Coco F, Diverio D, Falda M, Ferrara F, Lazzarino M, Russo D, Petti MC, Mandelli F.

Blood. 1996 Aug 15;88(4):1390-8.

15.

A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.

Xin L, Wan-jun S, Zeng-jun L, Yao-zhong Z, Yun-tao L, Yan L, Chang-chun W, Qiao-chuan L, Ren-chi Y, Ming-zhe H, Jian-xiang W, Lu-gui Q.

Leuk Res. 2007 Jun;31(6):765-71. Epub 2006 Sep 27.

PMID:
17007927
16.

Therapy of molecular relapse in acute promyelocytic leukemia.

Lo Coco F, Diverio D, Avvisati G, Petti MC, Meloni G, Pogliani EM, Biondi A, Rossi G, Carlo-Stella C, Selleri C, Martino B, Specchia G, Mandelli F.

Blood. 1999 Oct 1;94(7):2225-9.

17.

High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia.

Kühnl A, Gökbuget N, Stroux A, Burmeister T, Neumann M, Heesch S, Haferlach T, Hoelzer D, Hofmann WK, Thiel E, Baldus CD.

Blood. 2010 May 6;115(18):3737-44. doi: 10.1182/blood-2009-09-241943. Epub 2010 Jan 11.

18.

Prognostic implication of BAALC gene expression in adult acute myeloid leukemia.

Yahya RS, Sofan MA, Abdelmasseih HM, Saudy N, Sharaf-Eldein MA.

Clin Lab. 2013;59(5-6):621-8.

PMID:
23865362
19.

High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.

Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrózek K, Baldus CD, Vukosavljevic T, Liu CG, Ross ME, Powell BL, de la Chapelle A, Kolitz JE, Larson RA, Marcucci G, Bloomfield CD; Cancer and Leukemia Group B (CALGB).

Blood. 2008 Jun 1;111(11):5371-9. doi: 10.1182/blood-2007-11-124958. Epub 2008 Mar 31.

20.

Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.

Marasca R, Zucchini P, Galimberti S, Leonardi G, Vaccari P, Donelli A, Luppi M, Petrini M, Torelli G.

Haematologica. 1999 Nov;84(11):963-8.

Supplemental Content

Support Center